Bridge: Bridging Anticoagulation for Patients with Atrial Fibrillation
The Bridge study will determine whether a bridging blood thinner called dalteparin is helpful or harmful for people with atrial fibrillation who stop taking warfarin in preparation for surgery or another procedure.
You may be eligible for this study if you:
Are 18 years of age or older
Have chronic atrial fibrillation
Have been treated with Coumadin for at least three months
This is a partial list of eligibility and exclusion criteria. To inquire whether you are eligible for this study, please call the contact number provided. If you choose to inquire via email, please refer to the study title in your correspondence.